What happens if I overdose Vancomycin HCl Donga?
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center ( http://www.aapcc.org), or emergency room immediately.
Proper storage of Vancomycin HCl Donga capsules:
Store Vancomycin HCl Donga capsules at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Vancomycin HCl Donga capsules out of the reach of children and away from pets.
Overdose of Vancomycin HCl Donga in details
If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
Notes
Do not share this medication with others.
This medication has been prescribed for your current condition only. Do not use it later for another infection unless your doctor directs you to do so. A different medication may be necessary in that case.
Lab and/or medical tests (such as kidney function, Vancomycin HCl Donga blood levels, cultures, complete blood counts) should be done while you are using this medication. Keep all medical and lab appointments.
Missed Dose
For the best possible benefit, it is important to receive each scheduled dose of this medication as directed. If you miss a dose, contact your doctor or pharmacist right away to establish a new dosing schedule. Do not double the dose to catch up.
Storage
Consult the product instructions or your pharmacist for storage details. Keep all medications away from children and pets.
Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
What should I avoid while taking Vancomycin HCl Donga?
Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, stop using Vancomycin HCl Donga and call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.
Vancomycin HCl Donga warnings
Oral Use Only
This preparation for the treatment of colitis is for oral use only and is not systemically absorbed. Vancomycin HCl Donga Hydrochloride Capsules must be given orally for treatment of staphylococcal enterocolitis and Clostridium difficile-associated diarrhea.
Orally administered Vancomycin HCl Donga Hydrochloride Capsules are not effective for other types of infections.
Parenteral administration of Vancomycin HCl Donga is not effective for treatment of staphylococcal enterocolitis and C. difficile-associated diarrhea. If parenteral Vancomycin HCl Donga therapy is desired, use an intravenous preparation of Vancomycin HCl Donga and consult the package insert accompanying that preparation.
Potential for Systemic Absorption
Clinically significant serum concentrations have been reported in some patients who have taken multiple oral doses of Vancomycin HCl Donga Hydrochloride Capsules for active C. difficile-associated diarrhea. Some patients with inflammatory disorders of the intestinal mucosa also may have significant systemic absorption of Vancomycin HCl Donga. These patients may be at risk for the development of adverse reactions associated with higher doses of Vancomycin HCl Donga Hydrochloride Capsules; therefore, monitoring of serum concentrations of Vancomycin HCl Donga may be appropriate in some instances, e.g., in patients with renal insufficiency and/or colitis or in those receiving concomitant therapy with an aminoglycoside antibiotic.
Nephrotoxicity
Nephrotoxicity (e.g., reports of renal failure, renal impairment, blood creatinine increased) has occurred following oral Vancomycin HCl Donga Hydrochloride Capsules USP therapy in randomized controlled clinical studies, and can occur either during or after completion of therapy.
The risk of nephrotoxicity is increased in patients >65 years of age.
In patients >65 years of age, including those with normal renal function prior to treatment, renal function should be monitored during and following treatment with Vancomycin HCl Donga Hydrochloride Capsules USP to detect potential Vancomycin HCl Donga induced nephrotoxicity.
Ototoxicity
Ototoxicity has occurred in patients receiving Vancomycin HCl Donga. It may be transient or permanent. It has been reported mostly in patients who have been given excessive intravenous doses, who have an underlying hearing loss, or who are receiving concomitant therapy with another ototoxic agent, such as an aminoglycoside. Serial tests of auditory function may be helpful in order to minimize the risk of ototoxicity.
Superinfection
Use of Vancomycin HCl Donga Hydrochloride Capsules may result in the overgrowth of nonsusceptible bacteria. If superinfection occurs during therapy, appropriate measures should be taken.
Development of Drug-Resistant Bacteria
Prescribing Vancomycin HCl Donga Hydrochloride Capsules in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria.
What should I discuss with my healthcare provider before taking Vancomycin HCl Donga?
Some medical conditions may interact with First-Vancomycin HCl Donga 25 solution. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
- if you are pregnant, planning to become pregnant, or are breast-feeding
- if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
- if you have allergies to medicines, foods, or other substances
- if you have kidney problems, colitis or other inflammation of the bowel, or hearing problems
Some MEDICINES MAY INTERACT with First-Vancomycin HCl Donga 25 solution. Tell your health care provider if you are taking any other medicines, especially any of the following:
- Aminoglycosides (eg, tobramycin) because the risk of kidney problems or hearing problems may be increased
- Methotrexate because the risk of its side effects may be increased by First-Vancomycin HCl Donga 25 solution
This may not be a complete list of all interactions that may occur. Ask your health care provider if First-Vancomycin HCl Donga 25 solution may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Vancomycin HCl Donga precautions
Oral Use Only
This preparation for the treatment of colitis is for oral use only and is not systemically absorbed. Vancomycin HCl Donga Hydrochloride Capsules must be given orally for treatment of staphylococcal enterocolitis and Clostridium difficile-associated diarrhea.
Orally administered Vancomycin HCl Donga Hydrochloride Capsules are not effective for other types of infections.
Parenteral administration of Vancomycin HCl Donga is not effective for treatment of staphylococcal enterocolitis and C. difficile-associated diarrhea. If parenteral Vancomycin HCl Donga therapy is desired, use an intravenous preparation of Vancomycin HCl Donga and consult the package insert accompanying that preparation.
Potential for Systemic Absorption
Clinically significant serum concentrations have been reported in some patients who have taken multiple oral doses of Vancomycin HCl Donga Hydrochloride Capsules for active C. difficile-associated diarrhea. Some patients with inflammatory disorders of the intestinal mucosa also may have significant systemic absorption of Vancomycin HCl Donga. These patients may be at risk for the development of adverse reactions associated with higher doses of Vancomycin HCl Donga Hydrochloride Capsules; therefore, monitoring of serum concentrations of Vancomycin HCl Donga may be appropriate in some instances, e.g., in patients with renal insufficiency and/or colitis or in those receiving concomitant therapy with an aminoglycoside antibiotic.
Nephrotoxicity
Nephrotoxicity (e.g., reports of renal failure, renal impairment, blood creatinine increased) has occurred following oral Vancomycin HCl Donga Hydrochloride Capsules USP therapy in randomized controlled clinical studies, and can occur either during or after completion of therapy.
The risk of nephrotoxicity is increased in patients >65 years of age.
In patients >65 years of age, including those with normal renal function prior to treatment, renal function should be monitored during and following treatment with Vancomycin HCl Donga Hydrochloride Capsules USP to detect potential Vancomycin HCl Donga induced nephrotoxicity.
Ototoxicity
Ototoxicity has occurred in patients receiving Vancomycin HCl Donga. It may be transient or permanent. It has been reported mostly in patients who have been given excessive intravenous doses, who have an underlying hearing loss, or who are receiving concomitant therapy with another ototoxic agent, such as an aminoglycoside. Serial tests of auditory function may be helpful in order to minimize the risk of ototoxicity.
Superinfection
Use of Vancomycin HCl Donga Hydrochloride Capsules may result in the overgrowth of nonsusceptible bacteria. If superinfection occurs during therapy, appropriate measures should be taken.
Development of Drug-Resistant Bacteria
Prescribing Vancomycin HCl Donga Hydrochloride Capsules in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria.
What happens if I miss a dose of Vancomycin HCl Donga?
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
References
- DrugBank. "VANCOMYCIN". http://www.drugbank.ca/drugs/DB00512 (accessed September 17, 2018).
- MeSH. "Anti-Bacterial Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
